Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 2:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 53 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Ophthalmic Emulsion Clear all
Withdrawn Phase 4 Interventional

Topical Corticosteroid Use in Addition to Oral Antivirals for Prevention of Recurrence of Herpes Simplex Virus (HSV) Keratitis

NCT03626376
View directory record Official record
Conditions
Herpes Simplex Virus Keratitis
Interventions
oral acyclovir 400 mg BID OR valacyclovir 500 mg qdaily, oral acyclovir 400 mg BID OR valacyclovir 500 mg qdaily + topical corticosteroid eye drops
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 13, 2022 · Synced Sep 2, 2026, 2:18 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of CBT-004 in Patients With Vascularized Pinguecula

NCT04884256
View directory record Official record
Conditions
Pinguecula
Interventions
CBT-004
Drug
Lead sponsor
Cloudbreak Therapeutics, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Sep 2, 2026, 2:18 AM EDT
Withdrawn Phase 3 Interventional Accepts healthy volunteers

Novel Use of Restasis and PROSE Devices

NCT04735510
View directory record Official record
Conditions
Ocular Surface Disease
Interventions
cyclosporine ophthalmic emulsion 0.05%
Drug
Lead sponsor
Boston Sight
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Needham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Sep 2, 2026, 2:18 AM EDT
Active, not recruiting Phase 3 Interventional

A Clinical Trial on Safety and Efficacy of CBT-001 in Patients With Pterygium

NCT05456425
View directory record Official record
Conditions
Pterygium
Interventions
CBT-001, Vehicle
Drug
Lead sponsor
Cloudbreak Therapeutics, LLC
Industry
Eligibility
12 Years and older
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
20
States / cities
Dothan, Alabama • Sun City, Arizona • Bakersfield, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2025 · Synced Sep 2, 2026, 2:18 AM EDT
Completed Phase 2 Interventional Results available

Lotemax® Gel 0.5% and Restasis 0.05% in Participants With Mild or Moderate Keratoconjunctivitis Sicca (Dry Eye Disease)

NCT01817582
View directory record Official record
Conditions
Keratoconjunctivitis Sicca
Interventions
Lotemax, Restasis, Soothe® Lubricant Eye Drops
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
40 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Aug 29, 2019 · Synced Sep 2, 2026, 2:18 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Restasis for Treatment of Brittle Nails

NCT00986427
View directory record Official record
Conditions
Brittle Nails
Interventions
Restasis (cyclosporine ophthalmic emulsion) 0.05%, Refresh® Dry Eye therapy
Drug
Lead sponsor
Julian M. Mackay-Wiggan
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 19, 2013 · Synced Sep 2, 2026, 2:18 AM EDT
Completed Phase 3 Interventional

Six Month Clinical Research Study for Patients With Moderate or Severe Dry Eye Syndrome

NCT00025818
View directory record Official record
Conditions
Keratoconjunctivitis Sicca, Sjogren's Syndrome, Lupus Erythematosus, Systemic, Arthritis, Rheumatoid, Scleroderma, Systemic
Interventions
Ophthalmic Emulsion
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
17
States / cities
La Jolla, California • Los Angeles, California • Waterbury, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated May 29, 2011 · Synced Sep 2, 2026, 2:18 AM EDT
Completed Phase 2 Interventional Results available

Ph2 Placebo-Controlled Study for Safety & Ocular Efficacy of SBI-100 Ophthalmic Emulsion in Pts w/ Elevated Eye Pressure

NCT06144918
View directory record Official record
Conditions
Primary Open Angle Glaucoma, Ocular Hypertension
Interventions
SBI-100 Ophthalmic Emulsion, 0.5%, SBI-100 Ophthalmic Emulsion, 1.0%, SBI-100 Ophthalmic Emulsion, Placebo
Drug
Lead sponsor
Skye Bioscience, Inc.
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
3
States / cities
Glendale, California • Newport Beach, California • Cranberry Township, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Sep 2, 2026, 2:18 AM EDT
Completed Not applicable Interventional

Efficacy of Cyclosporine Ophthalmic Emulsion in the Treatment of Dry Eye Syndrome in Contact Lens Wearers

NCT00335114
View directory record Official record
Conditions
Contact Lens Wearers With Dry Eye Syndrome
Interventions
cyclosporine ophthalmic emulsion
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 8, 2023 · Synced Sep 2, 2026, 2:18 AM EDT
Completed Phase 2 Interventional Results available

CyclASol for the Treatment of Moderate to Severe Dry-eye Disease (DED)

NCT02617667
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Cyclosporine A, Placebo
Drug
Lead sponsor
Novaliq GmbH
Industry
Eligibility
18 Years to 99 Years
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
4
States / cities
Newport Beach, California • Lewiston, Maine • Andover, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2019 · Synced Sep 2, 2026, 2:18 AM EDT
Completed Not applicable Interventional Results available

The Efficacy of an Ocular Emulsion in Meibomian Gland Dysfunction

NCT01207752
View directory record Official record
Conditions
Meibomian Gland Dysfunction
Interventions
Systane Balance, Optive Lubricant Eye Drops
Drug
Lead sponsor
Southern California College of Optometry at Marshall B. Ketchum University
Other
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Fullerton, California
Source: ClinicalTrials.gov public record
Updated Mar 31, 2025 · Synced Sep 2, 2026, 2:18 AM EDT
Completed No phase listed Observational

An Observational Study to Assess Next Generation Emulsion Preservative Free Eye Drops (NGE-UD) on Dry Eye Symptoms and Quality of Life of Adult Participants With Mild to Moderate Dry Eye Disease (DED)

NCT06443775
View directory record Official record
Conditions
Dry Eye
Interventions
Next Generation Emulsion Preservative Free Eye Drops (NGE-UD)
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Town and Country, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 13, 2025 · Synced Sep 2, 2026, 2:18 AM EDT
Completed Phase 4 Interventional

Efficacy of Cyclosporine for the Prevention and Treatment of Dry Eye Symptoms Following LASIK or Photorefractive Keratectomy

NCT00349440
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Cyclosporine, Refresh Plus
Drug
Lead sponsor
Innovative Medical
Industry
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Greensboro, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 25, 2008 · Synced Sep 2, 2026, 2:18 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Effect of a New Emulsion in Dry Eye Patients on Tear Layer Aberrometry, Contrast Sensitivity, and Reading Ability

NCT01013077
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
Optive, Soothe, New Emulsion, Soothe, New Emulsion, Optive, New Emulsion, Optive, Soothe
Other
Lead sponsor
Southern California College of Optometry at Marshall B. Ketchum University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Fullerton, California
Source: ClinicalTrials.gov public record
Updated Jun 11, 2025 · Synced Sep 2, 2026, 2:18 AM EDT
Recruiting Phase 2 Interventional

Evaluation of TL-925 for the Treatment of Allergic Conjunctivitis

NCT06686472
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
TL-925, Placebo
Drug
Lead sponsor
Telios Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 12, 2024 · Synced Sep 2, 2026, 2:18 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Comparing Treatment of Dry Eye With Intracanalicular Dexamethasone, Restasis, and/or Lotemax

NCT04555694
View directory record Official record
Conditions
Dry Eye
Interventions
Cyclosporine, Loteprednol Etabonate, Dexamethasone Ophthalmic 0.4 Mg Ophthalmic Insert
Drug
Lead sponsor
Thomas Chester, OD
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Brecksville, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Sep 2, 2026, 2:18 AM EDT
Completed Phase 3 Interventional Results available

Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder

NCT00755040
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
cyclosporine ophthalmic emulsion, placebo
Drug · Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
5
States / cities
Palo Alto, California • Chicago, Illinois • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2017 · Synced Sep 2, 2026, 2:18 AM EDT
Completed Phase 2 Interventional

A Study Of TL-925 For The Treatment of AC

NCT06293820
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
TL-925, Placebo
Drug
Lead sponsor
Telios Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 2, 2024 · Synced Sep 2, 2026, 2:18 AM EDT
Completed Phase 2 Interventional Results available

A Research Study To See How Well an Eye Drop, SURF-100 (A Mycophenolic Acid/Betamethasone Sodium Phosphate Combination), Works and What Side Effects There Are in Subjects With Dry Eye Disease

NCT04734197
View directory record Official record
Conditions
Dry Eye Disease
Interventions
SURF-100 (Combination of 0.3% Mycophenolic Acid and 0.01% Betamethasone Sodium Phosphate), Mycophenolic Acid 0.1%, Mycophenolic Acid 0.3%, Betamethasone Sodium Phosphate 0.01%, Placebo Comparator: Vehicle, Cyclosporine 0.05% Ophthalmic Emulsion, Lifitegrast 5% Ophthalmic Solution
Drug
Lead sponsor
Surface Ophthalmics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
349 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
40
States / cities
Phoenix, Arizona • Azusa, California • Hemet, California + 33 more
Source: ClinicalTrials.gov public record
Updated May 10, 2025 · Synced Sep 2, 2026, 2:18 AM EDT
Completed Phase 2 Interventional

NOVA22007 0.05% and 0.1% Cyclosporine Versus Vehicle for the Treatment of Dry Eye

NCT00739349
View directory record Official record
Conditions
Dry Eye
Interventions
NOVA22007 ''Cyclosporine'', vehicle/placebo
Drug
Lead sponsor
Santen SAS
Industry
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Lewiston, Maine
Source: ClinicalTrials.gov public record
Updated Jun 5, 2016 · Synced Sep 2, 2026, 2:18 AM EDT
Completed Phase 3 Interventional Results available

Double-Masked Trial of NOVA22007 (1mg/mL Ciclosporin/Cyclosporine) Versus Vehicle in Pediatric Patients With Active Severe Vernal Keratoconjunctivitis

NCT01751126
View directory record Official record
Conditions
Vernal Keratoconjunctivitis
Interventions
NOVA22007 ''Ciclosporin'', Placebo
Drug
Lead sponsor
Santen SAS
Industry
Eligibility
4 Years to 18 Years
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
4
States / cities
Glendale, California • Irvine, California • Rancho Cordova, California + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2022 · Synced Sep 2, 2026, 2:18 AM EDT
Completed Phase 2 Interventional

Treatment of Dry Eye Syndrome With Cyclosporin A Eye Drops

NCT00001731
View directory record Official record
Conditions
Keratoconjunctivitis Sicca, Sjogren's Syndrome
Interventions
Cyclosporin A
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 2, 2026, 2:18 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of Catioprost® (Unpreserved Latanoprost 0.005% Emulsion) Compared to Travatan Z® to Treat Glaucoma and Ocular Surface Disease

NCT01254370
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension, Ocular Surface Disease
Interventions
Latanoprost, Travatan Z
Drug
Lead sponsor
Santen SAS
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 5, 2016 · Synced Sep 2, 2026, 2:18 AM EDT
Completed No phase listed Observational Results available

Efficacy Study of Cyclosporine Ophthalmic Emulsion in Patients With Dry Eye Disease

NCT00717418
View directory record Official record
Conditions
Keratoconjunctivitis Sicca
Interventions
cyclosporine ophthalmic emulsion 0.05%, artificial tears
Drug
Lead sponsor
Allergan
Industry
Eligibility
Not listed
Enrollment
781 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Wilson, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 11, 2012 · Synced Sep 2, 2026, 2:18 AM EDT